Multiple myeloma (MM), a plasma cell malignancy, has seen dramatic improvements in survival over the last two decades with the advent of immunomodulatory agents, proteasome inhibitors, and anti-CD38 targeted monoclonal antibodies.48 The gene discussed is CD38; the disease is plasma cell myeloma.